News about LLY

Jim Cramer said even tech-focused insiders favor Eli Lilly, with one predicting the drugmaker could eventually reach a $2 trillion market capitalization. Billionaire investor Ken Langone had predicted Lilly would top a $1 trillion market cap, which happened nearly a year ago; it now stands at a $1.2 trillion valuation. Lilly has emerged as the dominant GLP-1 player, and its shares closed at a record high above $1,306 on Oct. 22 before drifting lower. The CNBC Investing Club holds a hold-equivalent 2 rating on the stock, and Lilly is up 10.5% month-to-date versus 2.8% for the Dow, 0.3% for the S&P 500 and a 2.4% loss for the Nasdaq. Lilly reports third-quarter earnings Thursday, with investors watching growth in its weight-loss business, especially Foundayo.

Apple (AAPL), Eli Lilly (LLY) and Coca-Cola (KO) all reached new 52-week highs this week, representing technology growth, healthcare innovation and defensive consumer staples. Apple, near $350, is supported by renewed iPhone momentum and fiscal Q3 revenue of $109.41 billion (up 16%). Eli Lilly hit $1,321.21, driven by obesity and diabetes drugs; Q2 revenue rose 48% to $23 billion and full-year revenue guidance was raised to $85-$87 billion. Coca-Cola, near $95, pays a $2.12 annualized dividend with a 2.2% yield and has raised its dividend for 64 consecutive years. The article says valuations after recent rallies may warrant caution, but the three stocks have durable competitive advantages and are worth considering for long-term portfolios.

Eli Lilly's exploratory Phase 3b TOGETHER-PsO data showed that combining Taltz with Zepbound in adults with moderate-to-severe plaque psoriasis and obesity or overweight changed far more immune and metabolic biomarkers than Taltz alone, with broader responses emerging as early as Week 12. The findings point to a possible immunometabolic link between psoriasis and obesity, which could let Lilly pair its immunology and obesity portfolios. The article says the data does not materially change the near-term focus on obesity and diabetes volumes or the risks from GLP-1 pricing pressure and litigation. It also cites Phase 2b EloraTZP results combining eloralintide with tirzepatide. The article's investment narrative projects $118.9 billion in revenue and $50.1 billion in earnings by 2029, implying a fair value of $1,329, about 12% above the current price.